Key Highlights
- Candel Therapeutics shares fell 26.10% by the close on Friday, November 13, 2026.
- No company-specific catalyst was reported for the decline.
- The clinical-stage company is advancing toward a year-end Biologics license application filing.
- Rising yields and a technology selloff weighed on speculative healthcare stocks.
Candel Therapeutics (NASDAQ:CADL), a clinical-stage biotechnology company developing viral immunotherapies for cancer, was among the session's steepest decliners on Friday, November 13, 2026, with its shares falling 26.10% by the close. No company-specific catalyst was reported to explain a drop of that magnitude. The move reflected the pronounced Volatility that defines small, pre-commercial biotechnology stocks, with no disclosed trial result, regulatory decision, financing or corporate announcement behind it.
Biotech Volatility Without a Catalyst
Clinical-stage biotech names like Candel are inherently binary and sentiment-driven. Their value rests on expectations about programs still working their way through development and toward regulatory milestones, and the company is advancing toward a year-end biologics license application filing for a prostate cancer therapy. Because so much of the Investment case sits in the future, these shares often swing dramatically on shifts in risk appetite, on routine portfolio repositioning, or on the ordinary push and pull of a thin order book, even when nothing fundamental has changed. A one-day move of more than a quarter is not unusual for a stock of this type.
The broader market offered little support for speculative, long-duration equities. Friday's defining macro event was the October Producer Price Index, released before the open, which rose 6.5% from a year earlier, the largest annual increase since November 2022, even as the monthly 0.3% gain undershot expectations slightly. The hot annual reading lifted Treasury yields, with the 10-year climbing roughly 5 basis points to around 5.15%, its highest since October, while markets leaned toward a likely Federal Reserve rate move at the December meeting and the CBOE Volatility index pushed above 20. Rising yields are especially unkind to companies whose anticipated profits lie years away, a description that fits a development-stage drug developer closely, and firmer volatility tends to shrink the appetite for exactly this kind of risk.
Tech Selloff Spreads Risk Aversion
Compounding the pressure was a technology-led decline that colored the whole session. The technology sector fell about 2% in its second consecutive daily drop, with the epicenter at Nvidia (NASDAQ:NVDA), which slid to fresh 52-week lows a day after co-founder and chief executive Jensen Huang resigned after 33 years; finance chief Colette Kress is serving as interim CEO while the board searches for a successor. While that story centered on chips and AI infrastructure, the risk-off tone it generated radiated across the market's more speculative corners, biotech among them.
The headline indexes finished mixed and relatively contained, which highlights how the sharpest moves were concentrated in individual, higher-risk names. The S&P 500 slipped 0.4% to close at 7,561.67 and the Nasdaq Composite fell 0.9% to 25,136.27, while the Dow Jones Industrial Average edged up about 0.1% to 52,347.55. Even so, it marked the market's first winning week since early October, with the S&P 500 gaining 2.5% across the five sessions. The smaller-company Russell 2000, a better comparison for a stock of Candel's size, eased 0.3% to 2,790.49.
A Biotech Slide on Sentiment Alone
For Candel, a clinical-stage biotech fell sharply on a day when rising inflation-driven yields and a technology selloff sapped risk appetite, with no company-specific news behind the slide. Stocks of this kind can move quickly in either direction on sentiment alone.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...